Scopus BioPharma Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 11.61 million compared to USD 26.95 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 1.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0011 USD | -47.62% | 0.00% | -97.45% |
1st Jan change | Capi. | |
---|---|---|
-97.45% | 88.38K | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SCPS Stock
- News Scopus BioPharma Inc.
- Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022